相关实验视频

Updated: May 27, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

3.9K

阿米万塔马布加上拉泽提尼布与奥西默提尼布在一线EGFR突变的先进非小细胞肺癌中

Nazmul Hasan1, Misako Nagasaka1

  • 1University of California Irvine School of Medicine, Orange, CA, USA.

Expert review of respiratory medicine
|February 18, 2025
PubMed
概括

新的组合疗法正在改善EGFR突变非小细胞肺癌 (NSCLC) 的一线治疗,比以前的单剂选择提供更高的疗效.

关键词:
皮肤表皮生长因子受体.弗拉拉拉,这是一个很好的例子.在FLAURA-2中,我们可以看到FLAURA-2.马里波萨 (MARIPOSA) 是一种植物.前线治疗的第一线治疗.氨酸激酶抑制剂 氨酸激酶抑制剂

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.7K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K